Vaxxinity, Inc.
DelistedCIK 1851657fmd_02F47A6486N1JXW5FHM98A309KManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Dec 31, 2023, 14 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|
| Total revenues | 1 | 0 | 0 | – |
| Cost of revenue | 0 | 2 | 0 | – |
| Gross profit | 1 | (2) | 0 | – |
| Research and development | 21 | 71 | 48 | 36 |
| Total operating expenses | 33 | 123 | 76 | 58 |
| Operating income | (32) | (125) | (76) | (58) |
| Interest expense | 1 | 1 | 1 | 1 |
| Interest and investment income | – | 0 | 1 | 2 |
| Other non-operating income (expense) | – | (12) | 1 | 1 |
| Income before taxes | (40) | (137) | (75) | (57) |
| Income tax expense | 0 | 0 | 0 | – |
| Net income from continuing operations | (40) | (137) | (75) | – |
| Net income | (40) | (137) | (75) | (57) |